Hostname: page-component-78c5997874-m6dg7 Total loading time: 0 Render date: 2024-11-18T00:16:01.921Z Has data issue: false hasContentIssue false
  • English
  • Français

Parasite vaccines versus anti-parasite drugs: rivals or running mates?

Published online by Cambridge University Press:  06 April 2009

W. E. Gutteridge
W. E. Gutteridge
Affiliation:
Wellcome Research Laboratories, Langley Court, Beckenham, Kent BR3 3BS., UK
Get access Rights & Permissions [Opens in a new window]

Summary

Previous articles in this volume have considered the whole question of parasite vaccines from the immunological point of view. A backcloth of general concepts (Roitt, 1989) and strategies in the viral area (Schild, 1989) precedes consideration of problems specific to parasite vaccines (Mitchell, G. F. 1989). This leads on to reviews of progress to date in the development of vaccines for leishmaniasis (Modabber, 1989), malaria (Mitchell, G. H. 1989) and schistosomiasis (Sher, 1989) and in the development and use of veterinary vaccines (Morrison, 1989). I have been asked in this final chapter to take one step back from all of this and provide the alternative, chemotherapeutic, perspective. The reasons for the request are particularly pertinent, though rarely stated: antiparasite drugs already exist; if parasite vaccines are in fact developed, the way these drugs are used and the whole question of whether or not new ones are required, will have to be reconsidered. It is also a timely one: it is clear that the whole concept of a series of vaccines for the control of parasitic diseases has been so well sold, some would say oversold, that it is impacting on the resolve within the pharmaceutical industry to undertake new chemotherapeutic developments, at a time when this is already under severe strain because of financial considerations (Gutteridge, 1987 a). Hence my title: Parasite vaccines versus anti-parasite drugs: rivals or running mates?. I will try to answer it by, in turn, addressing three key questions. Why are we attempting to develop parasite vaccines? Will we be successful? If we are, will there still be a need for chemotherapy?

Keywords

anti-parasite drugsvaccineschemotherapy
Type
Research Article
Information
Parasitology , Volume 98 , supplement S1: Symposia of the British Society for Parasitology Volume 26:Vaccines and vaccination strategies , January 1989 , pp. S87 - S97
Copyright
Copyright © Cambridge University Press 1989

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

Anderson, R. M. (1988). Epidemiological models and predictions. Tropical and Geographical Medicine 40, 530–9.Google ScholarPubMed
Anonymous, (1987). WHO Expert Committee on Onchocerciasis. Technical Report Series 752. Geneva: World Health Organization.Google Scholar
Asquith, p. (1980). The clinical use of levamisole – a critical review. In Recent Advances in Clinical Immunology, Vol. 2 (ed. Thompson, R. A.), pp. 341–60. Edinburgh: Churchill Livingstone.Google Scholar
Awadzi, A., Dadzie, K. Y., Schulz-key, H., Haddock, D. R. W., Gilles, H. M. & Aziz, M. A. (1984). Ivermectin in onchocerciasis. Lancet ii, 921.CrossRefGoogle Scholar
Bennett, J. L., Williams, J. F. & Dave, V. (1988). Pharmacology of ivermectin. Parasitology Today 4, 226–8.CrossRefGoogle ScholarPubMed
Bergman, T. (1987). Quinolones. In The Antimicrobial Agents Annual 2 (ed. Peterson, P. K. and Verhoef, J.), pp. 169–83. Amsterdam: Elsevier.Google Scholar
Bitonti, A. J., Mccann, P. P. & Sjoerdsma, A. (1986). Necessity of antibody response in the treatment of African trypanosomiasis with α-difluoromethylornithine. Biochemical Pharmacology 35, 331–4.CrossRefGoogle ScholarPubMed
Boothroyd, J. C. (1985). Antigenic variation in African trypanosomes. Annual Review of Microbiology 39, 475–502.CrossRefGoogle ScholarPubMed
Boudreau, E. F., Pang, L. W., Dixon, K. E., Webster, H. K., Pavanand, K., Tosingha, L., Somutsakorn, P. & Canfield, C. J. (1988). Malaria – treatment efficacy of halofantrine (WR-171,669) in initial field trials in Thailand. Bulletin of the World Health Organization 66, 227–31.Google ScholarPubMed
Brener, Z. (1986). Why vaccines do not work in Chagas disease. Parasitology Today 2, 196–7.CrossRefGoogle Scholar
Briceno-Leon, R. (1987). Rural housing for control of Chagas disease in Venezuela. Parasitology Today 3, 384–7.CrossRefGoogle ScholarPubMed
Butcher, G. A. (1988). Mechanisms of malarial immunity. Parasitology Today 4, 202.CrossRefGoogle ScholarPubMed
Campbell, W. C. (1985). Ivermectin: an update. Parasitology Today 1, 10–16.CrossRefGoogle ScholarPubMed
Coles, G. C., Bruce, J. I., Kinoti, G. K., Mutahi, W. T., Dias, L. C. S., Rocha, R. S. & Katz, N. (1988). The potential for drug resistance in schistosomiasis. Parasitology Today 3, 349.CrossRefGoogle Scholar
Corey, L. (1984). Epidemiology of infectious diseases. In Medicinal Microbiology. An Introduction to Infectious Diseases (ed. Sherris, J. C.), pp. 76–87. Amsterdam: Elsevier.Google Scholar
Cosgriff, T. M., Boudreau, E. F., Pamplin, C. L., Doberstyn, E. B., Desjardins, R. E. & Canfield, C. J. (1982). Evaluation of the antimalarial activity of the phenanthrenemethanol halofantrine (WR 171, 669). American Journal of Tropical Medicine and Hygiene 31, 1075–9.CrossRefGoogle ScholarPubMed
Currey, H. L. F. (1983). Drugs affecting the immune system. In Immunology in Medicine (ed. Holborow, E. J. and Reeves, W. G.), pp. 589–612. London: Grune and Stratton.Google Scholar
Dias, J. C. P. (1987). Control of Chagas disease in Brazil. Parasitology Today 3, 336–41.CrossRefGoogle ScholarPubMed
Dolin, R. (1987). Amantadine and rimantadine. In The Antimicrobial Agents Annual 2 (ed. Peterson, P. K. and Verhoef, J.), pp. 330–8. Amsterdam; Elsevier.Google Scholar
Fenner, F., Henderson, D. A., Arita, E., Jezek, Z. & Ladnyi, I. D. (1988). Smallpox and Its Eradication. Geneva: World Health Organization.Google Scholar
Geddes, A. M. (1985). The prescriber's needs for the developed and third worlds. In The Scientific Basis of Antimicrobial Chemotherapy (ed. Greenwood, D. and , F. O'Grady), pp. 1–12. Cambridge: Cambridge University Press.Google Scholar
Gilman, A. G., Goodman, L. S., Rall, T. W. & Murad, F. (eds.) (1985). The Pharmacological Basis of Therapeutics, 7th Edn. New York: Macmillan.Google Scholar
Goodwin, L. G. (1987). Chemotherapy and tropical disease: the problem and the challenge. In Chemotherapy of Tropical Diseases (ed. Hooper, M.), pp. 1–18. Chichester: John Wiley.Google Scholar
Graham, N. B. (1983). Controlled and directed drug delivery. In Modern Design of Antimalarial Drugs (ed. Wernsdorfer, W. and Trigg, P. I.), pp. 151–72. Geneva: World Health Organization.Google Scholar
Gutteridge, W. E. (1982). Chemotherapy. In Modern Parasitology (ed. Cox, F. E. G.), pp. 287–318. Oxford: Blackwell.Google Scholar
Gutteridge, W. E. (1987 a). New antiprotozoal agents. International Journal for Parasitology 17, 121–30.CrossRefGoogle Scholar
Gutteridge, W. E. (1987 b). Available trypanocidal drugs. La Medicina Tropicale 3, 118–21.Google Scholar
Hannoun, C. (1978). Vaccines against influenza. In New Trends and Developments in Vaccines (ed. Voller, A. and Friedman, H.), pp. 63–9. Lancaster: MTP Press.CrossRefGoogle Scholar
Harnett, w. (1988). The anthelmintic action of praziquantel. Parasitology Today 4, 144–6.CrossRefGoogle ScholarPubMed
Hashemi-Fesharki, R. (1988). Control of Theileria annulata in Iran. Parasitology Today 4, 36–40.CrossRefGoogle ScholarPubMed
Horton, J. (1988). Introduction of halofantrine for malaria treatment. Parasitology Today 4, 238–9.CrossRefGoogle ScholarPubMed
Hotez, P. J., Le Trang, N. & Cerami, A. (1987). Hookworm antigens: the potential for vaccination. Parasitology Today 3, 247–9.CrossRefGoogle ScholarPubMed
Hughes, W. T. (1987). Treatment and prophylaxis for Pneumocystis carinii pneumonia. Parasitology Today 3, 332–5.CrossRefGoogle ScholarPubMed
Kaufmann, S. H. E. (1987). Towards new leprosy and tuberculosis vaccines. Microbiological Sciences 4, 324–8.Google ScholarPubMed
Kaye, P. M. (1987). Antigen presentation and the response to parasitic infection. Parasitology Today 3, 293–9.CrossRefGoogle ScholarPubMed
Klei, T. R. (1986). Development of vaccines against equine helminths. Parasitology Today 2, 80–1.CrossRefGoogle ScholarPubMed
Long, P. L. & Jeffers, T. K. (1986). Control of chicken coccidiosis. Parasitology Today 2, 236–40.CrossRefGoogle ScholarPubMed
Maddox, J. (1988). Finding the wood among the trees. Nature, London 333, 11.CrossRefGoogle ScholarPubMed
McDougald, L. R. (1982). Chemotherapy of coccidiosis. In The Biology of the Coccidia (ed. Long, P.), pp. 149–98. Baltimore: University Park Press.Google Scholar
McGregor, I. (1985). Malaria. In Epidemiology and the Community Control of Disease in Warm Climate Countries, 2nd Edn (ed. Robinson, D.), pp. 413–29. Edinburgh: Churchill Livingstone.Google Scholar
Mitchell, G. F. (1989). Problems specific to parasite vaccines. Parasitology 98, (Suppl.) S19–S28.CrossRefGoogle ScholarPubMed
Mitchell, G. H. (1989). An update on candidate malaria vaccines. Parasitology 98, (Suppl.) S29–S47.CrossRefGoogle ScholarPubMed
Modabber, F. (1989). Experiences with leishmania vaccines: from mice to men. Parasitology 98, (Suppl.) S49–S60.CrossRefGoogle Scholar
Morrison, I. (1989). Immunological control of livestock parasites. Parasitology 98, (Suppl.) S69–S85.CrossRefGoogle Scholar
Nantulya, V. M. (1986). Immunological approaches to the control of animal trypanosomiasis. Parasitology Today 2, 168–73.CrossRefGoogle Scholar
Poltera, A. A., Figueroa, R., Reyes, H., Koura, M. S. T. & Degen, R. (1986). Successful single low dose therapy in Giardia lamblia patients with Cibemide®, a new 5-nitroimidazole. Sixth International Congress of Parasitology, Brisbane, Abstract 516.Google Scholar
Poltera, A. A., Schuetzenberger, R., Guzman, Rumbea J., Ramirez, F. H. & Degen, R. (1986). Successful three day's therapy of amoebic liver abscess with Cibemide® a new 5-nitromidazole. Sixth International Congress of Parasitology, Brisbane, Abstract 517.Google Scholar
Pratt, W. B. (1973). Fundamentals of Chemotherapy. Oxford: Oxford Medical Publications.Google Scholar
Rajagopalan, P. K., Panicker, K. N. & Das, P. K. (1987). Control of malaria and filariasis vectors in South India. Parasitology Today 3, 233–41.CrossRefGoogle ScholarPubMed
Roitt, I. (1989). Basic concepts and new aspects of vaccine development. Parasitology 98, (Suppl.) S7–S12.CrossRefGoogle ScholarPubMed
Saag, M. S., Hahn, B. H., Gibbons, J., Li, Y., Parks, E. S., Parks, W. P. & Shaw, G. M. (1988). Extensive variation of human immunodeficiency virus type-I in vivo. Nature, London 334, 440–1.CrossRefGoogle ScholarPubMed
Sanders, C. C. & Sanders, W. E. Jr (1987). The cephalosporins and cephamycins. In The Antimicrobial Agents Annual 2 (ed. Peterson, P. K. and Verhoef, J.), pp. 70–95. Amsterdam: Elsevier.Google Scholar
Schechter, P. J. (1987). Effects on parasitic protozoa of eflornithine (DFMO): an inhibitor of polyamine biosynthesis. La Medicina Tropicale 3, 122–5.Google Scholar
Schild, G. C. (1989). Strategies for viral vaccines: scientific challenge and regulatory aspects. Parasitology 98, (Suppl.) S13–S18.Google ScholarPubMed
Schofield, C. J. (1985). Appropriate disease control. Parasitology Today 1, 181–2.CrossRefGoogle ScholarPubMed
Sharma, R. L., Bhat, T. K. & Dhar, D. N. (1988). Control of sheep lungworm in India. Parasitology Today 4, 33–6.CrossRefGoogle ScholarPubMed
Sher, A. (1989). Schistosome vaccines: current progress and future prospects. Parasitology 98, (Suppl.) 561–S68.CrossRefGoogle ScholarPubMed
Sherris, J. C. (1984). Antimicrobics and chemotherapy. In Medical Microbiology. An Introduction to Infectious Diseases (ed. Sherris, J. C.), pp. 123–49. Amsterdam: Elsevier.Google Scholar
Smith, J. T. (1985). The 4-quinolone antibacterials. In The Scientific Basis of Antimicrobial Chemotherapy (ed. Greenwood, D. and O'Grady, F.), pp. 69–94. Cambridge: Cambridge University Press.Google Scholar
Steinert, M. & Pays, E. (1986). Selective expression of surface antigen genes in African trypanosomes. Parasitology Today 2, 15–19.CrossRefGoogle ScholarPubMed
Wall, R. & Strong, L. (1987). Environmental consequences of treating cattle with the antiparasitic drug ivermectin. Nature, London 327, 418–21.CrossRefGoogle ScholarPubMed
Wall, R. & Strong, L. (1988). Ivermectin and cattle dung – a case for concern. Parasitology Today 4, 107–8.CrossRefGoogle Scholar
Webb, D. J. T. (1985). Low-cost housing and parasite vectors. Parasitology Today 1, 65–6.CrossRefGoogle ScholarPubMed
Weber, J. L. (1988). A review. Molecular biology of malaria parasites. Experimental Parasitology 66, 143–70.CrossRefGoogle ScholarPubMed
White, D. O. (1984). Antiviral Chemotherapy, Interferons and Vaccines. Basel: Karger.Google Scholar
Williams, D. N. (1986). Tetracyclines. In The Antimicrobial Agents Annual I (ed. Peterson, P. K. and Verhoef, J.), pp. 188–96. Amsterdam: Elsevier.Google Scholar
Wofsy, C. B. (1986). Antimicrobial therapy of infections in patients with acquired immunodeficiency syndrome. In The Antimicrobial Agents Annual 1 (ed. Peterson, P. K. and Verhoef, J.), pp. 377–400. Amsterdam: Elsevier.Google Scholar
Zimmerman, G. L. & Hoberg, E. P. (1988). Controlled release devices for delivery of anthelmintic drugs in cattle. Parasitology Today 4, 55–6.CrossRefGoogle Scholar